IP Library Granted Patent US 10,857,207
Granted Patent B2
US 10,857,207 · App. 15/910,876 · Granted Dec 8, 2020

Method of treating diabetes type 2 by administering ultrarapid acting insulin

Inventors: Peter Richardson (Ringoes, NJ); Robert A. Baughman (Brookfield, CT); Elizabeth Potocka (Cambridge, MA); Anders Hasager Boss (Princeton, NJ); Richard Petrucci (New Canaan, CT)
Assignee: MannKind Corporation
A61K38/28A61K9/0021A61K9/0075A61K47/545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,857,207
App. No.
15/910,876
Granted
Dec 8, 2020
Kind
B2
Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Claims (5)

1. A method of treating diabetes comprising: selecting a patient with diabetes and in need of improved glycemic control, administering to said patient a first dose of an inhalable ultrarapid acting insulin preparation with at least one established meal at mealtime, and administering a second dose of the inhalable ultrarapid acting insulin 30 to 120 minutes after starting the at least one established meal if blood glucose levels are greater than 140 mg/dL; wherein the first dose and the second dose of the ultrarapid acting insulin comprise up to 120 IU of total insulin in a preparation comprising microparticles of 3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine and recombinant human insulin.

2. The method of claim 1 wherein the ultrarapid acting insulin preparation is a dry powder.

3. The method of claim 1 , wherein the ultrarapid acting insulin preparation is provided in an inhaler system comprising 4, 8, or 12 unit dose cartridges.

4. The method of claim 3 , wherein the ultrarapid acting insulin preparation is a crystalline dry powder.

5. The method of claim 1 , wherein the second dose of the ultrarapid acting insulin is 25% to 100% of the first dose.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded Aug 12, 2025
From: MANNKIND CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072444/0525 →
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2018
From: RICHARDSON, PETER; BAUGHMAN, ROBERT A.; POTOCKA, ELIZABETH; BOSS, ANDERS HASAGER; PETRUCCI, RICHARD
To: MANNKIND CORPORATION
Reel/Frame 045399/0448 →